Korean J Nutr.  2009 Oct;42(7):605-614. 10.4163/kjn.2009.42.7.605.

Effect of High Protein Diet and Resveratrol Supplementation on the Nutritional Status and Immunoreactivity in the Irradiation-induced Inflammatory Rats

• Kim KO
• Chun M
• Kang S
• Kim HS

• KMID: 2267339
• DOI: http://doi.org/10.4163/kjn.2009.42.7.605

Abstract

Most cancer patients are treated with surgery, chemotherapy or radiation as anticancer therapies. Especially in the case of radiation, these treatments produce adverse effects such as vomiting, weight loss, anorexia, normal cell damage and malabsorption. The major goal of this study was to determine the effect of irradiation on the nutritional and immune status in irradiated rats. A secondary goal was to determine the effectiveness of high protein diet (HP) and resveratrol (Res) in minimizing the adverse effects of radiation. Rats were divided into four groups: normal diet (NP), HP, NP + Res and HP + Res groups. Each group was further divided into subgroups that received radiation (RT group) and one that did not (non-RT group). Each diet was supplied from 12th day prior to irradiation treatment with irradiation dose of 17.5 Gy. The diets were continued until 10th day after radiation treatment and animals were sacrificed. The radiation treatment showed decreased body weight, serum protein and HDL levels and increased TG and LDL levels in nutritional status. HP, NP + Res and HP + Res groups reduced the level of serum LDL and TG in irradiated rats. NP + Res and HP + Res groups increased reduced albumin level of serum in RT group. In case of immune status, the radiation treat-ment showed decreased WBC, lymphocytes and increased neutrophil and eosinophil levels. The levels of serum IL-2 and IL-6 were significantly increased by radiation, however the cytokine levels decreased in all dietary treatment groups. These results showed that high protein diet and resveratrol supplementation seem to minimize the adverse effects of radiation on lipid nutritional status and inflammation response in the rat model.

Keyword

radiation treatment; high protein diet; resveratrol; immunoreactivity; nutrition status

MeSH Terms

Animals
Anorexia
Body Weight
Diet
Eosinophils
Humans
Inflammation
Interleukin-2
Interleukin-6
Lymphocytes
Neutrophils
Nutritional Status
Rats
Stilbenes
Vomiting
Weight Loss
Interleukin-2
Interleukin-6
Stilbenes

Figure

• 

  Fig. 1 Body weight and food intakes of rats was measured before and after radiation. Each diet was supplied from 12th day prior to irradiation treatment with irradiation dose of 17.5 Gy in experimental groups, and was continued until 10th day after radiation treatment. Means with different letters are significantly different from each other at p < 0.05 as etermined by Duncan's multiple test. a < b.

• 

  Fig. 2 Total protein in serum of rats was measured 10th day after radiation. Each diet was supplied from 12th day prior to irradiation treatment with irradiation dose of 17.5 Gy in experimental groups, and was continued until 10th day after radiation treatment. Means with different letters are significantly different from each other at p < 0.05 as determined by Duncan's multiple test. a < b < c < d.

• 

  Fig. 3 Lipid status in serum of rats was measured 10th day after radiation. Each diet was supplied from 12th day prior to irradiation treatment with irradiation dose of 17.5 Gy in experimental groups, and was continued until 10th day after radiation treatment. Means with different letters are significantly different from each other at p < 0.05 as determined by Duncan's multiple test. a < b < c < d.

• 

  Fig. 4 IL-2, IL-6, IL-10 and IL-12 productions in serum of rats were-measured 10th day after radiation. Each diet was supplied from 12th day prior to irradiation treatment with irradiation dose of 17.5 Gy in experimental groups, and was continued until 10th day after radiation treatment. Means with different letters are significantly different from each other at p < 0.05 as determined by Duncan's multiple test. a < b < c < d.

Reference

1. Carmia Borek. Antioxidants and radiation therapy. J Nutr. 2004. 134(11):3207S–3209S.

2. Greenspan D. Xerostomia: Diagnosis and management. Oncology (Williston Park). 1996. 10:7–11.

3. Whitmyer CC, Waskowski JC, Iffland HA. Radiotherapy and oral sequelae: preventive and management protocols. J Dent Hyg. 1997. 71(1):23–29.

4. Jang HJ, Yu HS, Jeon MS, Jang GH, Lee JP. Comparison of Concurrent Chemoradiotherapy Regimen Toxicities in the Treatment of Loco-Regionally Advanced Cervical Cancer. Korean J Obstet Gynecol. 2004. 47(5):908–916.

5. Hamberger AD, Unal A, Gershenson DM, Fletcher GH. Analysis of the severe complications of irradiation of carconoma of the cervix: whole pelvis irradiation and intracavitary radium. Int J Radiat Oncol Biol Phys. 1983. 9:367–371.

6. Weijl NI, Cleton FJ, Osanto S. Free radicals and antioxidants in chemotherapy-induced tosicity. Cancer Treat Rev. 1997. 23:209–240.

7. Sangeetha P, Das UN, Koratkar R, Suryaprabha P. Increase in free radical generation and lipid peroxidation following chemotherapy in patients with cancer. Free Radic Biol Med. 1990. 8:15–19.

8. Durken M, Agbenu J, Finckh B, Hübner C, Pichlmeier U, Eeller W, Winkler K, Zander A, Kohlschütter A. Deteriorating free radicaltrapping capacity and antioxidant status in plasma during bone marrow transplantation. Bone Marrow Transplant. 1995. 15:757–762.

9. Lauterburg BH, Nguyen T, Hartmann B, Junker E, Kupfer A, Cerny T. Depletion of total cysteine, glutathione, and homocysteine in plasma by ifosfamide/mesna therapy. Cancer Chemother Pharmacol. 1994. 35:132–136.

10. Vidal Alfonso, de la Cuerda Cristina, Luis Escat Jose, Breton Irene, Camblor Miguel, Garcia-Peris Pilar. Chronic radiation enteritis after ovarian cancerFrom home parenteral nutrition to oral diet. Clin Nutr. 2006. 25:701–704.

11. Galland BB, Spencer J. Natural history and surgical management of radiation enteritis. Br J Surg. 1987. 74:742–747.

12. Leiro J, Arranz JA, Fraiz N, Sanmartín ML, Quezada E, Orallo F. Effect of cis-resveratrol on genes involved in nuclear factor kappa B signaling. Int Immunopharmacol. 2005. 5(2):393–406.

13. Delmas D, Lancon A, Colin D, Jannin B, Latruffe N. Resveratrol as a chemopreventive agent: a promising molecule for fighting cancer. Current Drug Targets. 2006. 7(4):423–442.

14. Faber AC, Chiles TC. Resveratrol induces apoptosis in transformed follicular lymphoma OCI-LY8 cells: evidence for a novel mechanism involving inhibition of BCL6 signaling. Intern J Oncology. 2006. 29(6):1561–1566.

15. Riles WL, Erickson J, Nayyar S, Atten MJ, Attar BM, Holian O. Resveratrol engages selective apoptotic signals in gastric adenocarcinoma cells. World J Gastroenterology. 2006. 12(35):5628–5634.

16. Sareen D, van Ginkel PR, Takach JC, Mohiuddin A, Darjatmoko SR, Albert DM, Polans AS. Mitochondria as the primary target of resveratrol-induced apoptosis in human retinoblastoma cells. Investigative Ophthamology & Visual Science. 2006. 47(9):3708–3716.

17. Faith SA, Sweet TJ, Bailey E, Booth T, Docherty JJ. Resveratrol suppresses nuclear factor-kappaB in herpes simplex virus infected cells. Antiviral Research. 2006. 72(3):242–251.

18. Palamara AT, Nencioini L, Aquilano K, et al. Inhibition of influenza A virus replication by resveratrol. J Infectious Diseases. 2005. 191(10):1719–1729.

19. Chun MS, Kang SH, Jin YM, Oh YT, Kil HJ, Ahn BO, Oh TY. Radiation-Induced Proctitis in Rand and Role of Nitric Oxide. J Korean Soc Ther Radiol Oncol. 2001. 19(3):265–274.

20. Dunlop R. Bruera E, Higginson I, editors. Clinical epidemiology of cancer cachexia. Cachexia-anorexia in cancer patients. 1996. Oxford: Oxford University Press;76–82.

21. MacDonald N, Easson NM, Mazurak VC, Dunn GP, Baracos VE. Understanding and managing cancer cachexia. J Am Coll Surg. 2003. 197:143–161.

22. Hutton Joanne L, Martin Lisa, Field Catherine J, Wismer Wendy V, Bruera Eduardo D, Watanabe Sharon M, Baracos Vickie E. Dietry patterns in patients with advanced cancer: implications for anorexia-cachexia therapy. Am J Clin Nutr. 2006. 84:1163–1170.

23. Igura K, Ohta T, Kuroda Y, Kaji K. Resveratrol and quercetin inhibit angiogenesis in vitro. Cancer Lett. 2001. 171:11–16.

24. Weiss JF, Landauer MR. Protection against ionizing radiation by antioxidant nutrients and phytochemicals. Toxicology. 2003. 189:1–20.

25. Borek C. Antioxidant health effects of aged garlic extract. J Nutr. 2001. 131:1010S–1015S.

26. Gridley DS, Makinde AY, Luo X, Rizvi A, Crapo JD, Dewhirst MW, Moeller BJ, Pearlstein RD, Slater JM. Radiation and a metalloporphyrin radioprotectant in a mouse prostate tumor model. Anticancer Res. 2007. 27(5A):3101–3109.

27. Sagar SM, Yance D, Wong RK. Natural health products that inhibit angiogenesis: a potential source for investigational new agents to treat cancer-part 2. Current Oncology. 2006. 13(3):99–107.

28. Cole AT, Slater K, Sokal M, Hawkey CJ. In vivo rectal inflammatory mediator changes with radiotherapy to the pelvis. Gut. 1993. 34(9):1210–1214.

29. Kim TI, Park HJ, Moon HY, Song SY, Kim GE, Cho NH, Park IS. Clinical Investigations Chronic Radiation Proctitis. Korean J Gastroenterol. 1996. 28:28–35.

30. Harding RK, Leach KE, Prud'home-Lalonde L, Ferrarotto CL. Release of inflammatory mediators from irradiated gastrointestinal tissue. Gastroenterology. 1990. 102:A258.

31. Lauritsen K, Laursen LS, Bukhave K, Rask-Madsen J. Effects of topical 5-aminosalicylic acid and prednisolone on prostaglandin E2 and leukotriene B4 levels determined by equilibrium in vivo dialysis of rectum in relapsing ulcerative colitis. Gastroenterology. 1986. 91:837–844.

32. Chen Y, Williams J, Ding I, Hernady E, Liu W, Smudzin T, Finkelstein JN, Rubin P, Okunieff P. Radiation pneumonitis and early circulatory cytokines markers. Semin Radiat Oncol. 2002. 12:26–33.

33. Chen Y, Rubin P, Williams J, Hernady E, Smudzin T, Okunieff P. Circulating IL-6 as a predictor of radiation pneumonitis. Int J Radiat Oncol Biol Phys. 2001. 49(3):641–648.

34. Indaram AV, Visvalingam V, Locke M, Bank S. Mucosal cytokine production in radiation-induced proctosigmoiditis compared with inflammatory bowel disease. Am J Gastroenterol. 2000. 95(5):1221–1225.

35. Athar M, Back JH, Kopelovich L, Bickers DR, Kim AL. Multiple molecular targets of resveratrol: Anti-carcinogenic mechanisms. Arch Biochem Biophys. 2009. 486(2):95–102.

36. Goswami SK, Das DK. Resveratrol and chemoprevention. Cancer Lett. 2009. 284(1):1–6.

37. Brisdelli F, D'Andrea G, Bozzi A. Resveratrol: a natural polyphenol with multiple chemopreventive properties. Curr Drug Metab. 2009. 10(6):530–546.

38. Li T, Fan GX, Wang W, Li T, Yuan YK. Resveratrol induces apoptosis, influences IL-6 and exerts immunomodulatory effect on mouse lymphocytic leukemia both in vitro and in vivo. Int Immunopharmacol. 2007. 7(9):1221–1231.

39. Gao Xiaohua, Xu Yong X, Janakiraman Nalini, Chapman Robert A, Gautam Subhash C. Immunomodulatory activity of resveratrol: suppression of lymphocyte proliferation, development of cell-mediated cytotoxicity, and cytokine production. Biochemical Pharmacology. 2001. 62:1299–1308.